Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.